-+ 0.00%
-+ 0.00%
-+ 0.00%

Changes in Hong Kong stocks | Cinda Biotech (01801) rose more than 2%, partner Ollin will be acquired by Johnson & Johnson, core phase 3 assets IBI/OLN324 will be incorporated into the Johnson & Johnson pipeline

Zhitongcaijing·11/19/2026 02:57:03
Listen to the news

The Zhitong Finance App learned that Cinda Biotech (01801) rose more than 2%. As of press release, it had risen 1.68% to HK$84.9, with a turnover of HK$255 million.

According to the news, Johnson & Johnson recently announced the acquisition of Ollin Biosciences with a down payment of US$2.2 billion, plus regulatory and commercialization milestone payments of up to US$1,125 million, with a total transaction price of up to US$3.325 billion. UBS pointed out that Cinda Biotech's partner Ollin will be acquired by Johnson & Johnson, and the core three-phase asset IBI/OLN324 (Ang2/VEGF) will be incorporated into the Johnson & Johnson pipeline. The bank has a positive view on this.

UBS believes the deal confirms Cinda Biotech's strength in ophthalmology research and development, including an advance payment of US$2.2 billion and a milestone payment of up to US$1,125 million. IBI/OLN324 in WAMD/DME phase 1b clinical data were positive compared to faricimab. Kuroishi will pay Johnson & Johnson USD 750 million to fully fund the OLN324 Phase III clinical trial in exchange for certain milestones and unit royalties.